Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs GEN 003 (Primary) ; Matrix M
- Indications Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors Genocea Biosciences
- 28 Jul 2016 Status changed from active, no longer recruiting to completed.
- 01 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 May 2016 as per ClinicalTrials.gov record.
- 01 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.